Centessa Pharmaceuticals Announces Poster Presentation At 26th Conference of the European Sleep Research Society
BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that non-clinical data from its oral orexin receptor 2 (OX2R) agonist discovery pipeline have been
Relmada Therapeutics Announces Completion Of Treatment In Company’s Registrational Phase 3 RELIANCE III Trial For Rel-1017 As A Monotherapy For Major Depressive Disorder
Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the completion of patient treatment in RELIANCE III, a monotherapy
OptimizeRx Extends Exclusive Partnership With Therapy Brands
Innovative best-in-class technology solutions continue to offer HCPs a seamless prescribing experience within the EHR workflow
Zai Lab To Present Analysis Of The Impact Of Timing For ZEJULA Maintenance Treatment In Newly Diagnosed Advanced Ovarian Cancer At The 2022 International Gynecologic Cancer Society Meeting September 29 – October 1, 2022
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)))), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will
MyMD Pharmaceuticals Provides Dosing Update On Phase 2 Multi-Center Clinical Trial Of MYMD-1; Efficacy Data Anticipated In Q4
MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and
Applied Molecular Transport Completes Enrollment Of Phase 2 LOMBARD Monotherapy Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis
Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-101 in 105 patients with
China-Based COVID-19 Shot Neutralizes Omicron Subvariants
China-based Clover Biopharmaceuticals Ltd announced data from its ongoing Phase 3 study evaluating SCB-2019 (CpG 1018/Alum) as a universal COVID-19 booster…
BiondVax Provides Update On Research Collaboration With Max Planck And UMG
JERUSALEM, Sept. 20, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and